

1/18

FIG. 1A 4D9Q VH

32716-VH QIQLVQSGPELKKPGETVKISCKASGYIFETNYGMNWVKQAPGKS**E**KWMGWINTYTGESTYSADFEKG
 h32716-VH1 QVQLVQSGPELKKPGASVKVSCASGYIFETNYGMNWVRQAPGGGLEWMGWINTYTGESTYSADFEKG
 h32716-VH2 QVQLVQSGPELKKPGASVKVSCASGYIFETNYGMNWVKQAPGGGLEWMGWINTYTGESTYSADFEKG
 h32716-VH3 QVQLVQSGPELKKPGASVKVSCASGYIFETNYGMNWVKQAPGGG**E**KWMGWINTYTGESTYSADFEKG

Cont. 32716-VH RFAFSLETSASTAYLHINDLKNEEDTATYFCARSGGYDPMGYWGQGTSTVTSS
 Cont. h32716-VH1 RFVFSLDTSVSTAYLQISSSLKAEDTAVYYCARSGGYDPMGYWGQGTSTVTSS
 Cont. h32716-VH2 RFVFSLDTSVSTAYLQISSSLKAEDTAVYYCARSGGYDPMGYWGQGTSTVTSS
 Cont. h32716-VH3 RFVFSLDTSVSTAYLQISSSLKAEDTAVYYCARSGGYDPMGYWGQGTSTVTSS

FIG. 1B 4D9Q VL

32716-VL DIVLTQSPASLAVSLGQRATISCRASESVSDNYGNTEMHWYQQKPGQPPKLLIYRASNLDSGI PARF
 h32716-VL1 DIQMTQSPSSLSASVGDRTITCRASESVSDNYGNTEMHWYQQKPGKAPKLLIYRASNLDSGVPDRF

Cont. 32716-VL SGSGSRTDFTLTINPVEADDVATYYCQQSNEDPPTFGAGTKLELK
 Cont. h32716-VL1 SGSGSGTDFTFTISSSLQPEDVATYYCQQSNEDPPTFGQGTKEIK

FIG. 1C 4NWT VH

32716-VH QIQLVQSGPELKKPGETVKISCKASGYIFETNYGMNWVKQAPGKS**E**KWMGWINTYTGESTYSADFEKG
 h32716-VH4 QVQLVQSGAEVKKPGSSVKVSCASGYIFETNYGMNWVRQAPGGGLEWMGWINTYTGESTYSADFEKG
 h32716-VH5 QVQLVQSGAEVKKPGSSVKVSCASGYIFETNYGMNWVKQAPGGGLEWMGWINTYTGESTYSADFEKG
 h32716-VH6 QVQLVQSGAEVKKPGSSVKVSCASGYIFETNYGMNWVKQAPGGG**E**KWMGWINTYTGESTYSADFEKG

Cont. 32716-VH RFAFSLETSASTAYLHINDLKNEEDTATYFCARSGGYDPMGYWGQGTSTVTSS
 Cont. h32716-VH4 RVTITADESTSTAYMELSSLRSEDTAVYYCARSGGYDPMGYWGQGTSTVTSS
 Cont. h32716-VH5 **RFTFTL**DESTSTAYMELSSLRSEDTAVYYCARSGGYDPMGYWGQGTSTVTSS
 Cont. h32716-VH6 **RFTFTL**DESTSTAYMELSSLRSEDTAVYYCARSGGYDPMGYWGQGTSTVTSS

FIG. 1D 4NWT VL

32716-VL DIVLTQSPASLAVSLGQRATISCRASESVSDNYGNTEMHWYQQKPGQPPKLLIYRASNLDSGI PARF
 h32716-VL2 DIVMTQSPDSLAVSLGERATINCRASESVSDNYGNTEMHWYQQKPGQPPKLLIYRASNLDSGVPDRF

Cont. 32716-VL SGSGSRTDFTLTINPVEADDVATYYCQQSNEDPPTFGAGTKLELK
 Cont. h32716-VL2 SGSGSGTDFTLTISSSLQAEDVAVYYCQQSNEDPPTFGQGTREIK

Bold: residues from murine sequence-

Bold and underline VH-VL interface residues

2/18

FIG. 2A





FIG. 2B



3/18

FIG. 2C





FIG. 2D



4/18

FIG. 2E






FIG. 2F




5/18

FIG. 2G



6/18

FIG. 3



SUBSTITUTE SHEET (RULE 26)

7/18

FIG. 4A






FIG. 4B



8/18

FIG. 4C
h32716-4-2 IgM*



9/18

FIG. 5A






FIG. 5B



10/18

FIG. 6



11/18

FIG. 7A





FIG. 7B



12/18

FIG. 8




FIG. 9A





FIG. 9B



14/18

FIG. 10A

Vehicle




FIG. 10B

CD123xCD3 IgG #1




FIG. 10C

h32716-1-1 IgM @ 5mg/kg






FIG. 10D

h32716-1-1 IgM @ 15mg/kg




15/18

FIG. 11



16/18

FIG. 12



17/18

FIG. 13A




FIG. 13B




FIG. 13C





FIG. 13D



18/18

FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D

